• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom stock dips on missed Q2 projections with broader G7 launch ‘in coming weeks’

July 28, 2022 By Sean Whooley

Dexcom updated logoDexcom (Nasdaq:DXCM) shares took a hit after hours today on second-quarter results that came up shy of the consensus forecast.

Shares of DXCM were down 7.2% at $80.69 after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 2.4%.

The San Diego-based continuous glucose monitor (CGM) developer posted profits of $50.9 million, or 12¢ per share, on sales of $696.2 million for the three months ended June 30, 2022, for a 35.1% bottom-line slide despite sales growth of 17%.

Adjusted to exclude one-time items, earnings per share were 17¢, 2¢ behind Wall Street, where analysts were looking for sales of $698.55 million.

“In the second quarter, Dexcom advanced a number of key initiatives, including the expansion of our CGM portfolio strategy in international markets,” Dexcom Chair, President and CEO Kevin Sayer said in a news release. “We are excited for the rest of this year, particularly as we implement a broader launch of G7 in the coming weeks.”

The Dexcom next-generation G7 CGM is yet to receive U.S. approval, but won CE mark in March and the company highlighted an updated sensor algorithm for G7 that received CE mark this quarter, making the latest G7 sensor technology available to international markets.

Dexcom tightened its full-year revenue guidance range, with the company now expecting sales between $2.86 billion and $2.91 billion (17%-19% growth). The previous projection was for between $2.82 million and $2.94 billion (15% to 20% growth).

BTIG analyst Marie Thibault wrote in a report that commentary on the quarter remained “upbeat,” with new patient adds for the U.S. and international regions, plus expectations of accelerated U.S. growth in the second half of the year. However, the analyst did temper expectations on performance while remaining confident in the company’s ability to grow.

“We reduce our 2022 sales forecast and push some 2H22 revenue into 2023 to reflect the G7 FDA timeline,” Thibault wrote. “Though DXCM shares could be weak tomorrow, we remain bullish on long-term growth and the opportunity for CGM market expansion.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS